Synonym: 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; 3,4-DAA; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; Rizaben; SB-252218
CAS Number: 53902-12-8
Empirical Formula (Hill Notation): C18H17NO5
Molecular Weight: 327.33
MDL Number: MFCD00864787
Linear Formula: C18H17NO5
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
white to beige |
| form |
powder |
| InChI |
1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+ |
| InChI key |
NZHGWWWHIYHZNX-CSKARUKUSA-N |
| mp |
166.2-168.2 °C (lit.) |
| originator |
Kissei |
| Quality Level |
100  |
| SMILES string |
COc1ccc(C=CC(=O)Nc2ccccc2C(O)=O)cc1OC |
| solubility |
DMSO: >10 mg/mL |
| |
H2O: insoluble |
| storage temp. |
2-8°C |
| Application: |
The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells. |
| Biochem/physiol Actions: |
Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy. It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE). |
| Biochem/physiol Actions: |
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases. |
| Biochem/physiol Actions: |
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, inhibits mast cell degranulation, and inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. |
| Features and Benefits: |
This compound was developed by Kissei . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
10, 50 mg in glass bottle |
| Symbol |
 GHS07 |
| Signal word |
Warning |
| Hazard statements |
H302 |
| Hazard Codes |
Xn |
| Risk Statements |
22 |
| Safety Statements |
26-36 |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Purity |
≥98% (HPLC) |
| mp |
166.2-168.2 °C (lit.) |
| Storage Temp. |
2-8°C |
| UNSPSC |
41106500 |
